TY - RPRT
KW - Opioid-Related Disorders -- drug therapy
KW - pregnant women
KW - Buprenorphine, Naloxone Drug Combination -- therapeutic use
KW - Treatment Outcome
KW - Patient Safety
KW - Cost-Benefit Analysis
KW - Guidelines as Topic
KW - Canada
AU - Rob Edge
AU - Robyn Butcher
A1 - 
AB - The purpose of this report is to review and appraise the evidence for the clinical effectiveness, safety, and cost-effectiveness of various buprenorphine monoproducts and buprenorphine-naloxone combination formulations for UOD during pregnancy. Additionally, this report aims to review current evidence-based guidelines regarding appropriate buprenorphine formulation use for this population.
BT - CADTH rapid response report: summary with critical appraisal,; Variation: Rapid response report (Canadian Agency for Drugs and Technologies in Health)
C4 - This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.
C5 - Grey Literature; Healthcare Disparities; Opioids & Substance Use
CY - Ottawa
JF - CADTH rapid response report: summary with critical appraisal,; Variation: Rapid response report (Canadian Agency for Drugs and Technologies in Health)
LA - English
M1 - Report
N2 - The purpose of this report is to review and appraise the evidence for the clinical effectiveness, safety, and cost-effectiveness of various buprenorphine monoproducts and buprenorphine-naloxone combination formulations for UOD during pregnancy. Additionally, this report aims to review current evidence-based guidelines regarding appropriate buprenorphine formulation use for this population.
PP - Ottawa
PY - 2019
RN - https://www.ncbi.nlm.nih.gov/books/NBK545816/
SN - Series 1922-8147; National Library: 101755548
T1 - Buprenorphine for opioid use disorders during pregnancy: A review of comparative clinical effectiveness, safety, cost-effectiveness, and guidelines. (CADTH rapid response report: summary with critical appraisal)
T2 - CADTH rapid response report: summary with critical appraisal,; Variation: Rapid response report (Canadian Agency for Drugs and Technologies in Health)
TI - Buprenorphine for opioid use disorders during pregnancy: A review of comparative clinical effectiveness, safety, cost-effectiveness, and guidelines. (CADTH rapid response report: summary with critical appraisal)
U1 - Grey Literature; Healthcare Disparities; Opioids & Substance Use
U4 - This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.
U5 - https://www.ncbi.nlm.nih.gov/books/NBK545816/
UR - https://www.ncbi.nlm.nih.gov/books/NBK545816/
VO - Series 1922-8147; National Library: 101755548
Y1 - 2019
ER -